|SHPG Description: Shire plc, a biotech company, together with its subsidiaries, engages in the research, development, licensing, manufacture, marketing, distribution, and sale of medicines for patients with rare diseases and other select conditions. Its principal products for the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ, as well as ADDERALL XR and INTUNIV for the treatment of ADHD; and LIALDA/MEZAVANT for the treatment of ulcerative colitis. The company also offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema; GATTEX/REVESTIVE for the treatment of short bowel syndrome; and NATPARA/NATPAR used to control hypocalcemia in patients with hypoparathyroidism. In addition, it provides Fosrenol for the treatment of hyperphosphatemia in end stage renal disease. Further, the company licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Additionally, it focuses on its development resources on projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects, primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has collaboration and licensing activities with ArmaGen Inc.; Sangamo BioSciences, Inc.; and Shionogi Pharma, Inc. Shire plc was founded in 1986 and is based in Dublin, Ireland.